Overview
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with significant morbidity and mortality. High-quality real-world data is crucial for understanding comparative effectiveness, unmet needs, and safety, in this patient population. However, existing sources often lack clinical detail on biomarkers, oral therapies, and progression. This study introduces a comprehensive dataset from the UK Flatiron Health Research Database, which includes data provided by patients and collected by the National Health Service as part of their care and support for DLBCL.
By analyzing data from 990 patients diagnosed between 2011 and 2024, the study provides insights into patient demographics, clinical/disease characteristics, testing results, treatment regimens, and mortality. The dataset includes a high level of detail and completeness and aligns with clinical expectations in the UK.
Why this matters
This dataset fills critical gaps in existing DLBCL data by offering a detailed view of real-world treatment and outcomes in the UK. The ability to harmonize this dataset with international counterparts from the US, Germany, and Japan allows for a global perspective on DLBCL management. Such comprehensive data supports the development of personalized treatment strategies and highlights areas for improvement in clinical practice and paves the way for more effective interventions worldwide.